Doximity (DOCS) Company Report

Doximity reported strong financial results for the second quarter of fiscal 2026, with revenues rising 23.2% year over year to $168.5 million and adjusted earnings per share increasing 50% year over year to 45 cents.
The company experienced significant operational growth, including over 50% growth in AI Scribe and DoxGPT users and an expanded user base of 650,000 prescribers, contributing to $159.5 million in subscription revenues.
Doximity maintains a strong financial position with $169.2 million in cash and cash equivalents and projects fiscal year 2026 revenue between $640 million and $646 million and adjusted EBITDA between $351 million and $357 million.

Nov 7, 2025, 12:14 PM

Morningstar

DOCS Reports Strong Q2 2026 Results and Raises Full-Year Guidance

DOCS

Earnings

Guidance Update

Product Launch

DOCS reported strong Q2 2026 financial results with revenue of $168.5 million, a 23% year-over-year increase, and an adjusted EBITDA of $100.8 million, achieving a 60% margin.
The company raised its full fiscal year 2026 guidance, now expecting revenue between $640 million and $646 million and adjusted EBITDA between $351 million and $357 million, primarily due to the outperformance of its pharma business.
AI product adoption saw significant growth, with quarterly active prescribers of AI tools increasing over 50% from the prior quarter, and Doximity Scribe users nearly tripling versus Q1. The recent Pathway acquisition was fully integrated, enhancing Docs GPT with drug reference and access to over 2,000 medical journals.
AI-optimized integrated programs now account for over 40% of Q2 bookings, a substantial increase from less than 5% a year ago, leading to a more consistent and strategic upsell cycle.

Nov 6, 2025, 10:00 PM

Transcript

DOCS Reports Strong Q2 2026 Financials and AI Product Growth

DOCS

Earnings

Guidance Update

Product Launch

For the second quarter of fiscal year 2026, DOCS reported $168.5 million in revenue, representing 23% year-on-year growth, and an adjusted EBITDA of $100.8 million, with a 60% margin. Free cash flow increased 37% year-on-year to $91.6 million.
The company's AI initiatives saw significant progress, with the Pathway acquisition fully integrated into Docs GPT within seven weeks, enhancing its drug reference and medical journal access capabilities. Quarterly active users for AI Scribe nearly tripled versus Q1.
DOCS provided guidance for Q3 2026, expecting revenue between $180 million and $181 million and adjusted EBITDA between $103 million and $104 million. For the full fiscal year 2026, revenue is projected to be between $640 million and $646 million, with adjusted EBITDA between $351 million and $357 million.
Integrated programs, which are AI-optimized, represented over 40% of bookings in Q2, a significant increase from less than 5% a year ago, contributing to a stronger than typical Q2 and a more evenly distributed upsell cycle.
DOCS continued to gain market share, growing at about two times the market growth rate for calendar year 2025, with a 15% growth rate compared to an estimated market growth of 5% to 7%.

Nov 6, 2025, 10:00 PM

Transcript

Doximity Reports Strong Q2 2026 Financials and Raises Full-Year Guidance

DOCS

Earnings

Guidance Update

Product Launch

Doximity (DOCS) reported Q2 FY2026 revenue of $169 million, a 23% year-on-year increase, and an Adjusted EBITDA of $101 million, achieving a 60% margin.
The company raised its full fiscal year 2026 revenue guidance to a range of $640 million to $646 million and Adjusted EBITDA guidance to $351 million to $357 million.
Key growth drivers include AI-optimized integrated programs, which comprised over 40% of Q2 bookings (up from less than 5% a year ago), and a 100% year-over-year growth in SMB bookings.
Operational success was marked by a 50% increase in quarterly active prescribers utilizing AI tools and a nearly tripled number of quarterly active users for AI Scribe compared to Q1.
Doximity maintained a strong financial position with $878 million in cash, cash equivalents, and marketable securities and repurchased $21.9 million in shares during the quarter.

Nov 6, 2025, 10:00 PM

Transcript

Doximity Announces Fiscal Q2 2026 Financial Results and Updates Guidance

DOCS

Earnings

Guidance Update

Doximity reported total revenues of $168.5 million for its fiscal second quarter ended September 30, 2025, representing a 23% increase year-over-year.
Operating cash flow for Q2 2026 was $93.9 million, and free cash flow was $91.6 million, both up 37% year-over-year.
Adjusted EBITDA for the quarter increased 32% year-over-year to $100.8 million, achieving a 59.8% margin.
For fiscal Q3 2026, Doximity expects revenue between $180 million and $181 million and adjusted EBITDA between $103 million and $104 million.
The company updated its fiscal year 2026 guidance, projecting revenue between $640 million and $646 million and adjusted EBITDA between $351 million and $357 million.

Nov 6, 2025, 9:08 PM

8-K

Doximity Announces Fiscal 2026 Second Quarter Financial Results

DOCS

Earnings

Guidance Update

Doximity reported total revenues of $168.5 million for the fiscal 2026 second quarter ended September 30, 2025, marking a 23% year-over-year increase.
For the same period, net income was $62.1 million and non-GAAP net income reached $90.0 million.
Adjusted EBITDA grew 32% year-over-year to $100.8 million, achieving a 59.8% margin, while diluted net income per share was $0.31 and non-GAAP diluted net income per share was $0.45.
The company provided guidance for its fiscal third quarter ending December 31, 2025, projecting revenue between $180 million and $181 million and Adjusted EBITDA between $103 million and $104 million.
Doximity updated its guidance for the fiscal year ending March 31, 2026, forecasting revenue between $640 million and $646 million and Adjusted EBITDA between $351 million and $357 million.

Nov 6, 2025, 9:01 PM

Press Release

Earnings Transcripts

Quarterly earnings call transcripts for Doximity.

Q2 2026

Nov 6, 2025

→

Q1 2026

Aug 7, 2025

→

Q4 2025

May 15, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Jeff Tangney say about margins?What are Doximity's strategic priorities?How is Doximity positioned vs competitors?How did Doximity do last quarter?

Doximity (DOCS)

Analyst Earnings Quarterly Reports

Q2 2026

Q1 2026

Q4 2025

Q3 2025

Executives

Jeff Tangney

Anna Bryson

John Vaughan

Board Members

Kevin Spain

Kira Wampler

Phoebe Yang

Regina Benjamin

Timothy Cabral

Analyst Coverage

Allen Lutz

Elizabeth Anderson

Scott Schoenhaus

Brian Peterson

Craig Hettenbach

Ryan MacDonald

David Roman

Ryan Daniels

Steven Valiquette

Brian Tanquilut

Eric Percher

Jailendra Singh

Michael Cherny

Stan Berenshteyn

David Larsen

Glen Santangelo

Jared Haase

Jeffrey Garro

Jenny Cao

Jessica Tassan

Michael Turney

Richard Close

Alexei Gogolev

Anne McCormick

Anne Samuel

Daniel Christopher Clark

Derek Gross

Jamie Perse

Jenny Shen

Johnathan McCary

John Park

Nate Gross

Scott Berg

Stanislav Berenshteyn

Stephanie Davis

Vikram Kesavabhotla

Latest news

Earnings Transcripts

Q2 2026

Q1 2026

Q4 2025

Ask Fintool AI Agent